Seeking Alpha

Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its...

Shares of OxiGene (OXGN +31%) are soaring today after the company released results from its Phase 2 trial of Zybrestat, a potential treatment for patients with polypoidal choroidal vasculopathy, a degenerative eye disease with features similar to age-related macular degeneration. The data was presented today at the annual meeting of the American Academy of Ophthalmology.
Comments (1)
  • smokeyRose
    , contributor
    Comments (78) | Send Message
     
    Bought this stock years ago for $2.00 went up to $20.00!!! :)
    Bought it again today for 0.41 lets Hope for a Deja vu
    13 Nov 2012, 07:26 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector